null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223184

Enrollment

640

Registered

2016-04-26

Start date

2016-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
efficacy	—

Countries

Africa, Europe, Japan, North America, Oceania

Outcome results